PCSK9 and atherosclerosis: Cholestyramine is recommended in combination with statins and ezetimibe for patients with ASCVD or those at high risk for cardiovascular disease who have LDL-C levels above target and are unable to use PCSK9 inhibitors [+, IIb, C].